Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control

A method for ameliorating symptoms and/or treating type 2 diabetes and one or more associated pathological conditions (sequelae) in a human subject comprising the steps of:

• identifying the human subject in need of amelioration of the symptoms and/or treatment of type 2 diabetes and one or more associated pathological conditions (sequelae);
• and
• administering a therapeutically effective amount of a pharmaceutical composition to the human subject, wherein the composition comprises:
• curcumin, curcumin analogues, curcumin derivatives, curcuminoids or combinations thereof dissolved or dispersed in a suitable aqueous or non-aqueous medium, wherein the curcumin is enclosed in at least one of one or more liposomes, enclosed in a polymeric nanoparticle, conjugated to one or more biodegradable polymers or formulated into a liposome that is surrounded or incorporated into a polymeric nanoparticle;
• one or more anti-diabetic agents;
• and
• one or more optional excipients, diluents, extended or controlled release agents, lubricants, preservatives or any combinations thereof.

A method of providing enhanced glycemic control in type 2 diabetes, preventing or treating one or more pathological conditions associated with type 2 diabetes, or both in a human subject comprising the steps of:

• identifying the human subject in need of enhanced glycemic control in type 2 diabetes, prevention or treatment of one or more pathological conditions associated with type 2 diabetes, or both;
• and
• administering a therapeutically effective amount of a pharmaceutical composition to the human subject comprising:
• curcumin, curcumin analogues, curcumin derivatives, curcuminoids or combinations thereof dissolved or dispersed in a suitable aqueous or non-aqueous medium, wherein the curcumin is enclosed in at least one of one or more liposomes, enclosed in a polymeric nanoparticle, conjugated to one or more biodegradable polymers or formulated into a liposome that is surrounded or incorporated into a polymeric nanoparticle;
• and
• one or more anti-diabetic agents comprising DPP-4 inhibitors, insulin release sensitizers, glucagon modifiers or any combinations thereof.

A method of providing enhanced glycemic control in type 2 diabetes, preventing or treating one or more pathological conditions associated with type 2 diabetes, ameliorating adverse reactions associated with type 2 diabetes treatment or any combinations thereof in a human subject comprising the steps of:

• identifying the human subject in need of enhanced glycemic control in type 2 diabetes, prevention or treatment of one or more pathological conditions associated with type 2 diabetes, amelioration or prevention of adverse reactions associated with type 2 diabetes treatment or any combinations thereof;
• and
• administering a therapeutically effective amount of a pharmaceutical composition to the human subject comprising:
• curcumin, curcumin analogues, curcumin derivatives, curcuminoids or combinations thereof dissolved or dispersed in a suitable aqueous or non-aqueous medium, wherein the curcumin is enclosed in at least one of one or more liposomes, enclosed in a polymeric nanoparticle, conjugated to one or more biodegradable polymers or formulated into a liposome that is surrounded or incorporated into a polymeric nanoparticle;
• and
• one or more anti-diabetic agents comprising DPP-4 inhibitors, insulin release sensitizers, glucagon modifiers or any combinations thereof.

A method of providing enhanced glycemic control in type 2 diabetes, preventing or treating one or more pathological conditions associated with type 2 diabetes, ameliorating adverse reactions associated with type 2 diabetes treatment or any combinations thereof in a human subject comprising the steps of:

• identifying the human subject in need of enhanced glycemic control in type 2 diabetes, prevention or treatment of one or more pathological conditions associated with type 2 diabetes, amelioration or prevention of adverse reactions associated with type 2 diabetes treatment or any combinations thereof;
• and
• administering a therapeutically effective amount of a pharmaceutical composition to the human subject comprising:
• a therapeutically effective amount of a formulation comprising curcumin, curcumin analogues, curcumin derivatives, curcuminoids or combinations thereof enclosed in a liposome, and wherein the liposomes are enclosed in a polymeric nanoparticle, wherein the formulation inhibits a cardiac potassium channel blocking activity of curcumin;
• and
• one or more optional excipients, diluents, extended or controlled release agents, lubricants, preservatives or any combinations thereof.